This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Boehringer Ingelheim (Canada) Ltd., Boehringer Ingelheim International Gmbh. Active years: 2004-2010.
Location History:
- Laval, CA (2004)
- Montreal, CA (2010)
Company Filing History:
1 out of 62 
1 out of 1,560 
Years Active: 2004-2010
Title: The Innovative Contributions of Roger Maurice
Introduction
Roger Maurice is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of assays and protease production methods related to the Hepatitis C virus. With a total of 2 patents, his work has the potential to impact therapeutic approaches for viral infections.
Latest Patents
One of Roger Maurice's latest patents is the "Hepatitis C virus NS2/3 activity assay." This invention provides a novel assay for NS2/3 cleavage detection, allowing for the detection of the NS3 cleavage product in the presence of uncleaved NS2/3. The assay utilizes specific reaction conditions to discriminate between the activity of the resulting NS3 protease product and the NS3 protease activity of the uncleaved protein. This innovation creates a 'signal window' that facilitates the measurement of NS3 protease activity produced from the cleavage of NS2/3.
Another significant patent is for the "Purified active HCV NS2/3 protease." This method involves producing a refolded, inactive form of recombinantly produced NS2/3 protease. The process includes purifying the protease from inclusion bodies with a chaotropic agent and refolding it using a reducing agent and lauryldiethylamine oxide (LDAO). The invention also describes a method for activating the refolded inactive NS2/3 protease, which can be used to screen small molecules and ligands as potential inhibitors of NS2/3 protease, offering promising therapeutic avenues against HCV.
Career Highlights
Roger Maurice has worked with prominent companies in the pharmaceutical industry, including Boehringer Ingelheim International GmbH and Boehringer Ingelheim (Canada) Ltd. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.
Collaborations
Throughout his career, Roger has collaborated with notable colleagues such as Diane Thibeault and Daniel Lamarre. These partnerships have likely enriched his research and innovation efforts.
Conclusion
Roger Maurice's contributions to the field of biotechnology, particularly in relation to Hepatitis C, demonstrate his innovative spirit and commitment to advancing medical science. His patents reflect a deep understanding of viral mechanisms and potential therapeutic strategies.